Preliminary clinical application of an aromatase inhibitor and a gonadotropin-releasing hormone agonist combination for inoperable endometrial cancer patients with comorbidities: case report and literature review

References

• van der Steen-Banasik E, Christiaens M, Shash E, Coens C, Casado A, Herrera FG, Ottevanger PB, European Organisation for Research and Treatment of Cancer, Gynaecological Cancer Group (EORTC-GCG). Systemic review: Radiation therapy alone in medical non-operable endometrial carcinoma. Eur J Cancer (Oxford, England: 1990). 2016;65:172–81. doi:10.1016/j.ejca.2016.07.005.
   PubMed Web of Science ®Google Scholar
• Hsieh MC, Thompson T, Wu XC, Styles T, O'Flarity MB, Morris CR, Chen VW. The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients. Cancer Med. 2016;5(5):871–80. doi:10.1002/cam4.632. PMID:26773804
   PubMed Web of Science ®Google Scholar
• Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol: official journal of the European Society for Medical Oncology. 2016;27(1):16–41. doi:10.1093/annonc/mdv484. PMID:26634381
   PubMed Web of Science ®Google Scholar
• Lee WL, Yen MS, Chao KC, Yuan CC, Ng HT, Chao HT, Lee FK, Wang PH. Hormone therapy for patients with advanced or recurrent endometrial cancer. J Chin Med Assoc: JCMA. 2014;77(5):221–6. doi:10.1016/j.jcma.2014.02.007. PMID:24694672
   PubMed Web of Science ®Google Scholar
• Baker WD, Pierce SR, Mills AM, Gehrig PA, Duska LR. Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. Gynecol Oncol. 2017;146(1):34–8. doi:10.1016/j.ygyno.2017.04.006. PMID:28427775.
   PubMed Web of Science ®Google Scholar
• Gao C, Wang Y, Tian W, Zhu Y, Xue F. The therapeutic significance of aromatase inhibitors in endometrial carcinoma. Gynecol Oncol. 2014;134(1):190–5. doi:10.1016/j.ygyno.2014.04.060. PMID:24811574
   PubMed Web of Science ®Google Scholar
• Thangavelu A, Hewitt MJ, Quinton ND, Duffy SR. Neoadjuvant treatment of endometrial cancer using anastrozole: a randomised pilot study. Gynecologic Oncol. 2013;131(3):613–8. doi:10.1016/j.ygyno.2013.09.023. PMID:24076063
   PubMed Web of Science ®Google Scholar
• Bogliolo S, Gardella B, Dominoni M, Musacchi V, Cassani C, Zanellini F, De Silvestri A, Gaggero CR, Babilonti L, Spinillo A. Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma. Arch Gynecol Obstet. 2016;293(4):701–8. doi:10.1007/s00404-015-3974-9. PMID:26671487
   PubMed Web of Science ®Google Scholar
• Barker LC, Brand IR, Crawford SM. Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. Curr Med Res Opin. 2009;25(5):1105–9. doi:10.1185/03007990902860549. PMID:19301987
   PubMed Web of Science ®Google Scholar
• Altman AD, Thompson J, Nelson G, Chu P, Nation J, Ghatage P. Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study. J Obstet Gynaecol Canada: JOGC = Journal d'obstetrique et gynecologie du Canada: JOGC. 2012;34(7):664–72. PMID:22742486
   PubMedGoogle Scholar
• Teutonico D, Montanari S, Ponchel G. Leuprolide acetate: pharmaceutical use and delivery potentials. Expert Opin Drug Delivery. 2012;9(3):343–54. doi:10.1517/17425247.2012.662484. PMID:22335366
   PubMed Web of Science ®Google Scholar
• Wan J, Gao Y, Zeng K, Yin Y, Zhao M, Wei J, Chen Q. The levels of the sex hormones are not different between type 1 and type 2 endometrial cancer. Sci Rep. 2016;6:39744. doi:10.1038/srep39744. PMID:28000774
   PubMed Web of Science ®Google Scholar
• Grundker C, Gunthert AR, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol. 2002;146(1):1–14. doi:10.1530/eje.0.1460001. PMID:11751060
   PubMed Web of Science ®Google Scholar
• Wu HM, Cheng JC, Wang HS, Huang HY, MacCalman CD, Leung PC. Gonadotropin-releasing hormone type II induces apoptosis of human endometrial cancer cells by activating GADD45alpha. Cancer Res. 2009;69(10):4202–8. doi:10.1158/0008-5472.CAN-08-4591. PMID:19366794
   PubMed Web of Science ®Google Scholar
• Wu HM, Wang HS, Huang HY, Lai CH, Lee CL, Soong YK, Leung PC. Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2. BMC Cancer. 2013;13:300. doi:10.1186/1471-2407-13-300. PMID:23786715
   PubMed Web of Science ®Google Scholar
• Zhao LJ, Wei LH, Li XP, Wang JL. [Effect of gonadotropin-releasing hormone-I agonist and gonadotropin-releasing hormone-II on endometrial carcinoma cell lines with different states of PTEN]. Zhonghua fu chan ke za zhi. 2009;44(1):45–9. PMID:19563062
   PubMedGoogle Scholar
• Asbury RF, Brunetto VL, Lee RB, Reid G, Rocereto TF. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol. 2002;25(6):557–60. doi:10.1097/00000421-200212000-00004. PMID:12477997
   PubMed Web of Science ®Google Scholar
• Noci I, Borri P, Bonfirraro G, Chieffi O, Arcangeli A, Cherubini A, Dabizzi S, Buccoliero AM, Paglierani M, Taddei GL. Longstanding survival without cancer progression in a patient affected by endometrial carcinoma treated primarily with leuprolide. Br J Cancer. 2001;85(3):333–6. doi:10.1054/bjoc.2001.1900. PMID:11487260
   PubMed Web of Science ®Google Scholar
• Torrisi R, Rota S, Losurdo A, Zuradelli M, Masci G, Santoro A. Aromatase inhibitors in premenopause: Great expectations fulfilled? Crit Rev oncology/hematol. 2016;107:82–9. doi:10.1016/j.critrevonc.2016.08.009. PMID:27823654
   PubMed Web of Science ®Google Scholar
• White J, Kearins O, Dodwell D, Horgan K, Hanby AM, Speirs V. Male breast carcinoma: increased awareness needed. Br Cancer Res: BCR. 2011;13(5):219. doi:10.1186/bcr2930. PMID:22017761
   PubMed Web of Science ®Google Scholar
• Zhou H, Cao D, Yang J, Shen K, Lang J. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women. Int J Gynecol Cancer: official journal of the International Gynecological Cancer Society. 2017;27(6):1178–82. doi:10.1097/IGC.0000000000001008. PMID:28562472
   PubMed Web of Science ®Google Scholar